通过SLC7A11 - 定向的蛋白质体退化来提高癌症治疗的精密铁灭放大
SiJia Lin1,2, Lin Wang2, Xue Dong2
1Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, P. R. China.
Advanced healthcare materials
|December 30, 2025
概括
研究人员开发了一种针对SLC7A11的新型PROTAC分子,以耗尽GPX4,增强ferroptosis并抑制瘤生长. 这种方法通过破坏细胞抗氧化剂防御来提供癌症治疗的新策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 铁亡是一种依赖于铁的细胞死亡途径.
- 谷氨过氧化酶4 (GPX4) 通过其抗氧化活性限制了铁灭菌的有效性.
- 向GPX4是一种在癌症治疗中增强铁亡的策略.
研究的目的:
- 开发针对SLC7A11的蛋白质分解向仿真体 (PROTACs),以耗尽GPX4.
- 增强氧化应激并诱导癌细胞中的铁亡.
- 为了评估开发的PROTAC的抗瘤疗效.
主要方法:
- 通过将SLC7A11抑制剂 (硫沙拉) 与CRBN连接体 (波马利多米德) 结合,设计和合成一种双功能PROTAC (dSLC7A11).
- 通过PROTAC对SLC7A11的乌比基介导降解的评估.
- 在癌细胞中评估系统Xc-无活化,GPX4枯竭和氧化应激放大.
- 在体内研究以确定dSLC7A11.11的抗瘤疗效.
主要成果:
- 设计的PROTAC,dSLC7A11,有效地诱导了SLC7A11.1的随处可见中介降解.
- dSLC7A11 失活了囊/谷氨酸抗载体 (Xc-系统),导致GPX4的耗尽.
- 这导致了强化的氧化应激和癌细胞中强烈的铁灭诱导.
- 在体内,dSLC7A11表现出卓越的抗瘤功效,与单独的硫沙相比,抑制了超过65%的瘤生长.
结论:
- 开发了一种针对SLC7A11的新型PROTAC,用于强大的ferroptosis诱导.
- 这种PROTAC通过耗尽GPX4.4有效地破坏细胞抗氧化剂防御系统.
- 这些发现为癌症治疗建立了基于PROTAC的有希望的治疗方法.
相关概念视频
01:13The Proteasome
1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
02:18The Proteasome
10.0K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.0K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K